• Categories：Academy
• Time of issue：2024-11-21 16:23
• Views：

(Summary description)Novel choroidal biomarker in predicting treatment outcomes of PCV: 3D CVI! The research recently published in <Ophthalmic Research> innovatively investigated the relationship between multiple choroidal biomarkers, clinical parameters, and the response to 3-monthly anti-VEGF therapy in PCV eyes by using full range SS-OCTA. 54 patients were enrolled and underwent a comprehensive ophthalmic examination at the initial visit and follow-up. Choroid thickness (CT) and 3D CVI (the ratio of the choroidal vessel volume to the total choroid volume) in 6mm x 6mm full range SS-OCTA centered on the fovea were analyzed. The result showed that the higher CVI at baseline was the ONLY factor that correlated with the poor response after 3 monthly injections of anti-VEGF and the CVI value showed superior predictive ability compared with the CT value. In the other word, 3D CVI using full range SS-OCTA was a promising biomarker to predict the response to anti-VEGF treatment in PCV patients. “This biomarker could also be a useful tool to identify the population at risk of an inadequate response to anti-VEGF.” A 400kHz speed full range swept source OCTA (BMizar, TowardPi Medical) was used in this research to detect neovascularization and quantify the choroid vasculature with built-in algorithms. Automatic segmentation of the choroidal Haller's and Sattler's layer and choroid parameters such as 3D CVI are available on the device. This study was authored by Dr. Yue Zhang, etc. team of Prof. Xiaobing Yu from Department of Ophthalmology, Beijing Hospital. Link to origin text: https://lnkd.in/gZ8tcaB9